National trends in gabapentinoid prescribing in osteoarthritis
PHE ePoster Library. Wilkie R. Apr 9, 2019; 257467; 15258
Dr. Ross Wilkie
Dr. Ross Wilkie
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Abstract Background:
Amid a substantial increase in gabapentinoid prescribing in the United Kingdom, there are growing concerns over their increasing unlicensed ('off-label') use and potential for misuse. In osteoarthritis, one of the most common painful conditions in the adult population, there are anecdotal reports of increasing off-label gabapentinoid prescribing for pain control. Using national primary care data, we estimated the trend in the rate of new gabapentinoid prescriptions in patients with osteoarthritis and the proportion attributable to osteoarthritis.
: Patients aged 40+ years with a new diagnosis of osteoarthritis recorded between 1995-2015 were identified in the Clinical Practice Research Datalink and followed to first prescription of gabapentin or pregabalin, or other censoring event. We estimated the crude and age-standardised annual incidence rates of gabapentinoid prescribing in this cohort, and stratified rates by patient age, sex, geographical region, and time since osteoarthritis diagnosis. Using diagnostic codes around the date of first gabapentinoid prescription, we estimated the proportion of prescriptions attributable to osteoarthritis versus licensed indications.
: Of 383,680 newly diagnosed osteoarthritis cases, 35,031 were prescribed at least one gabapentinoid. The annual age-standardised incidence rate of first gabapentinoid prescriptions rose from 1.6 (95% CI: 1.3, 2.0) per 1,000 person-years in 2000, to 27.6 (26.7, 28.4) in 2015, a trend seen across all ages and not explained by length of follow-up. Rates were higher among women, younger ages, and in Northern Ireland, Scotland and the North of England. Approximately 9-10% of first prescriptions could be attributed to osteoarthritis, a further 11-12% to a comorbid licensed indication.Conclusion: Patients with osteoarthritis have become increasingly likely to receive a gabapentinoid. A significant proportion appears to be off-label use for osteoarthritis pain control despite little trial evidence of effectiveness. The effect of reclassifying gabapentinoids as class C drugs on osteoarthritis care and outcomes warrants investigation.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings